Alkermes
ALKS
#3068
Rank
$5.15 B
Marketcap
$31.22
Share price
1.96%
Change (1 day)
7.47%
Change (1 year)

P/E ratio for Alkermes (ALKS)

P/E ratio as of January 2026 (TTM): 15.1

According to Alkermes's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 15.0821. At the end of 2024 the company had a P/E ratio of 12.9.

P/E ratio history for Alkermes from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202412.9-0.04%
202312.9-147.4%
2022-27.2-64.89%
2021-77.5172.37%
2020-28.575.82%
2019-16.2
2017-53.130.98%
2016-40.6-22.32%
2015-52.2-82.16%
2014-293

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Acorda Therapeutics
ACOR
-0.0676-100.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
19.1 26.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
21.0 39.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
15.1-0.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
31.0 105.33%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
51.3 240.46%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Zogenix
ZGNX
-6.56-143.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
12.8-15.06%๐Ÿ‡ซ๐Ÿ‡ท France
Novartis
NVS
19.4 28.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.